Last reviewed · How we verify
TTYP01
At a glance
| Generic name | TTYP01 |
|---|---|
| Also known as | Edaravone tablets |
| Sponsor | Shanghai Auzone Biological Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease (PHASE2)
- Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD (PHASE2)
- Evaluate the Efficacy and Safety of TTYP01 Tablets in the Treatment of Acute Ischemic Stroke (PHASE3)
- A Study of TTYP01 in Healthy Adult Subjects (PHASE1)
- Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TTYP01 CI brief — competitive landscape report
- TTYP01 updates RSS · CI watch RSS
- Shanghai Auzone Biological Technology Co., Ltd. portfolio CI